B of A Securities Initiates Coverage On Avidity Biosciences With Buy Rating, Announces Price Target of $40
B of A Securities Initiates Coverage On Avidity Biosciences With Buy Rating, Announces Price Target of $40
B of A Securities以買入評級啓動對Avidity Biosciences的報道，宣佈目標股價爲40美元
B of A Securities analyst Geoff Meacham initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Buy rating and announces Price Target of $40.
B of A Securities分析師傑夫·米查姆以買入評級開始對Avidity Biosciences（納斯達克股票代碼：RNA）進行報道，並宣佈目標股價爲40美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。